SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Cell Stem Cell
Jie SunLing Li

Abstract

Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. Mechanistically, the inhibitory effects of SIRT1 were dependent on TET2, a safeguard against HSPC transformation. SIRT1 deacetylated TET2 at conserved lysine residues in its catalytic domain, enhancing TET2 activity. Our genome-wide analysis identified cancer-related genes regulated by the SIRT1/TET2 axis. SIRT1 activation also inhibited functions of MDS HSPCs from patients with TET2 heterozygous mutations. Altogether, our results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target MDS HSPCs.

Citations

May 16, 2019·Journal of Zhejiang University. Science. B·Fei-Teng HuangLing Li
Oct 4, 2019·Nature Reviews. Cardiology·Tatyana KuznetsovaMenno P J de Winther
Jun 9, 2020·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Casey Griffin, Jean-Pierre Saint-Jeannet
Apr 23, 2020·Cellular and Molecular Life Sciences : CMLS·Zhenhua Yang, Hao Jiang
Jun 27, 2019·British Journal of Haematology·Alfonso E Bencomo-AlvarezAnna M Eiring
Apr 20, 2019·Frontiers in Oncology·Yimei FengXi Zhang
Sep 9, 2020·Communications Biology·Yihong GuanBabal K Jha
Oct 30, 2020·International Journal of Molecular Sciences·Oleg Kandarakov, Alexander Belyavsky
Nov 9, 2020·Molecular Aspects of Medicine·George HajishengallisTriantafyllos Chavakis
Mar 16, 2019·Current Opinion in Chemical Biology·Tatsiana KosciukHening Lin
Apr 16, 2021·Cell Death & Disease·Lifeng FengHongchuan Jin
Apr 30, 2021·Journal of Cancer Research and Clinical Oncology·Jyoti ShekhawatMithu Banerjee
May 1, 2021·Cancers·Camilla Bertuzzo VeigaDragana Dragoljevic
May 19, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Lin ZhuLina Du
Jun 21, 2021·Biochimica Et Biophysica Acta. General Subjects·Liz M Garcia-Peterson, Xiaoling Li
Jul 3, 2021·International Journal of Molecular Sciences·Panagiota KaragianniMichael Voulgarelis
Jul 6, 2021·Frontiers in Cell and Developmental Biology·Jiaqi LiZhiguang Zhou
Aug 17, 2021·Frontiers in Immunology·Wanhai QinTom van der Poll
Sep 1, 2021·Cancer Discovery·Yasushige AoyagiHironori Harada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.